Journal of Clinical Oncology
Articles in this Issue
Characterization of hereditary tumor risk in individuals with SDHA germline variants.
10610 Background: Paragangliomas (PGLs) are rare neuroendocrine tumors with a high degree of heritability; up to 30% of individuals diagnosed with a PGL a...
Circulating tumor cells and clinical outcomes in men with metastatic hormone sensitive prostate cancer treated with enzalutamide and docetaxel: Analysis of the ENZADA trial.
e17093 Background: Circulating tumor cell enumeration is a minimally invasive biomarker that has been shown to be prognostic for overall survival (OS) in...
Metabolic-only response assessment for omission of residual node radiation therapy (RNRT) for patients with classical Hodgkin lymphoma (cHL) and impact on event free (EFS) and overall survival (OS): A report from the Pediatric Hodgkin Consortium’s phase 2 study cHOD17 (NCT03755804).
10018 Background: The AEPA/CAPDac (brentuximab vedotin, etoposide, prednisone, doxorubicin [cumulative dose = 160mg/m 2 ], cycloph...
Real world outcome analysis of the two McGill University–associated hospitals with Lu-177 PRRT for metastatic NET.
e16347 Background: Neuroendocrine tumours (NET) are a heterogenous group of neoplasms that arise from neuroendocrine cells within various organs. Their ag...
Empowering medical oncologists: Exploring the impact and engagement of telegram channels for professional development in Russia.
9041 Background: Social media use has gained popularity among medical professionals, with X being one of the most popular platforms globally by medical on...
Cohort builder in Tempus Lens: Querying a large oncology database with generative AI.
e13589 Background: Tempus Lens is a hosted web application that allows users to query multimodal data from millions of de-identified patient records in th...
Impact of rucaparib on circadian rhythms and adverse events in ovarian cancer: Insights from the MAMOC trial.
5578 Background: Ovarian cancer (OC) is a leading cause of gynaecologic cancer mortality, with most cases diagnosed at an advanced stage. Standard treatme...
Efficacy of low-dose nivolumab in advanced cancers: A retrospective analysis from medical oncology clinic in Eastern India.
2598 Background: Immunotherapy with PD-1/PDL1 blocking monoclonal antibodies has improved survival across several malignancies at different stages of thes...
Higher school of oncology: A decade of advancing oncology training in resource-limited settings.
e21028 Background: Postgraduate oncology training in resource-limited (RL) countries is often short and lacks structured curricula and a competency focus....
Effect of a multidisciplinary intervention based on a supervised training program on cardiovascular risk and quality of life in early stage breast cancer patients.
545 Background: There is growing evidence that physical activity can enhance cancer care. Exercise programs have been shown to help manage treatment side...
Association of radiomic features with disease-free survival following neoadjuvant chemoimmunotherapy in resectable NSCLC.
8077 Background: Neoadjuvant chemoimmunotherapy (chemo-IO) has emerged as a promising approach to improve disease-free survival (DFS) in patients with sur...
Comparison of <i>MET</i> genomic alterations (GA) identified in colorectal cancer (CRC) vs gastric cancer (GCA).
3570 Background: MET signaling promotes tumor progression and therapeutic resistance across many solid tumors through diverse oncogenic signaling pathways...
MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: Updated dose escalation results in the phase 1 KisMET-01 study.
8613 Background: MYTX-011 is a novel cMET-targeting vcMMAE ADC engineered for pH-dependent binding. This results in more efficient payload delivery, which...
Evaluating medication adherence and testosterone suppression in patients with prostate cancer treated with relugolix: Results from the OPTYX study.
e17106 Background: Relugolix is the only oral androgen deprivation therapy (ADT) for advanced prostate cancer (PC). In the phase 3 HERO trial, it showed r...
Nationwide analysis and trend of liver cancer mortality attributable to drug use in United States from 1991 to 2021.
10565 Background: Liver cancer attributable to drug use represents an escalating public health concern in the United States (US). This study analyzes mort...
Impact of year-end holidays on delayed cancer diagnoses and survival implications: A population-based study.
e13793 Background: Timely diagnosis and treatment initiation are critical for optimizing cancer survival outcomes. However, periods of reduced healthcare...
First public and private ovarian cancer register in Chile: Potential effect of national formulary inclusion and COVID-19 pandemic on survival outcomes.
e17586 Background: Ovarian cancer (OC) is considered the most aggressive gynecologic cancer, with a 5-year survival rate of 50.9%. In Chile, OC is conside...
Prognostic utility of a personalized ctDNA minimal residual disease test in patients undergoing curative resection of HPV-negative head and neck squamous cell carcinoma.
e18113 Background: Circulating tumor DNA (ctDNA) is emerging as a powerful prognostic biomarker as a minimal residual disease (MRD) test in the postoperat...
Surgery over radiation: A clear path for malignant phyllodes tumors.
e12576 Background: Malignant phyllodes tumors of the breast are rare fibroepithelial neoplasms with potential for local recurrence and metastasis. While s...
A phase 1, first-in-human study of regorafenib plus temozolomide with or without radiotherapy in patients with newly diagnosed MGMT methylated, IDHwt glioblastoma: The REGOMA-2 trial.
2068 Background: Regorafenib (REG) is an oral multikinase inhibitor and in vivo studies demonstrated a synergistic antitumor effect when combined with rad...
The incidence and impact of sepsis in patients hospitalized with cholangiocarcinoma: Findings from the Nationwide Inpatient Sample.
e16249 Background: Sepsis is a significant cause of morbidity and mortality in patients with cancer. This study examines the impact of sepsis on hospitali...
RYZ101 ( <sup>225</sup> Ac-DOTATATE) in patients with estrogen receptor-positive, human epidermal growth factor receptor 2–negative, locally advanced and unresectable, or metastatic breast cancer progressing after prior therapy: The phase 1b/2 TRACY-1 study.
TPS3184 Background: RYZ101 (actinium-225 [ 225 Ac]-DOTATATE) is a radiolabeled somatostatin analog (SSA) for the treatment of pati...
Clinical outcomes and safety of adjuvant therapy in patients with high-risk melanoma harboring BRAF V600 mutations: A multicenter, retrospective cohort study.
e21565 Background: High-risk melanoma encompasses deep primary tumors, with or without ulceration (stages IIB and IIC), as well as regional lymph node inv...
Profiling of exceptional responders (ER) and non-responders (NR) to androgen receptor pathway inhibitors (ARPI) in men with metastatic hormone sensitive and castration resistant prostate cancer.
e17107 Background: In clinical practicea subset of patients treated with androgen deprivation therapy (ADT) plus an ARPI achieve prolonged benefit (ER) wh...
Comparing traditional NLP methods and LLM-based extraction for identifying biomarkers in lung cancer.
e13607 Background: Lung cancer treatment relies heavily on genomic biomarkers, which are often recorded in unstructured documents like clinical notes. Ext...